{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:22:40Z","timestamp":1773526960108,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral treatment options for paediatric patients with moderate-to-severe plaque psoriasis are limited. In the 16-week double-blind placebo-controlled phase of the SPROUT trial, apremilast demonstrated efficacy vs. placebo in paediatric patients with psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the 52-week efficacy and safety of apremilast in SPROUT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SPROUT was a phase III multicentre randomized double-blind placebo-controlled parallel-group study (NCT03701763). Patients were randomized 2 : 1 to receive apremilast 20 or 30\u2005mg (for patients weighing 20 to &amp;lt; 50\u2005kg or \u2265 50\u2005kg at baseline, respectively) twice daily or placebo for 16 weeks, after which all patients received apremilast through week 52 (apremilast\/apremilast or placebo\/apremilast, respectively). Patients were aged 6\u201317\u2005years and had moderate-to-severe psoriasis that was inadequately controlled by or intolerant to topical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 245 patients randomized, 221 (apremilast\/apremilast, n = 149; placebo\/apremilast, n = 72) entered the apremilast extension phase and 186 (apremilast\/apremilast, n = 125; placebo\/apremilast, n = 61) completed 52 weeks. With continued apremilast treatment, rates of static Physician Global Assessment (sPGA) response (score of 0 or 1 with \u2265 2-point reduction from baseline) further improved from week 16 (30.1%) to week 52 (47.7%). In the placebo\/apremilast group, sPGA response rates increased from 9.8% at week 16 to 44.4% at week 52. The proportions of patients with \u2265 75% reduction from baseline in Psoriasis Area and Severity Index increased from 42.3% at week 16 to 60.4% at week 52 in the apremilast\/apremilast group and from 13.4% to 63.9% in the placebo\/apremilast group. No new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Improvements in clinical outcomes were sustained through 52 weeks with apremilast treatment in paediatric patients with moderate-to-severe psoriasis. Safety findings were consistent with the known safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf305","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:36:47Z","timestamp":1753789007000},"page":"1120-1127","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S","family":"Paller","sequence":"first","affiliation":[{"name":"Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children\u2019s Hospital , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-5485","authenticated-orcid":false,"given":"Loretta","family":"Fiorillo","sequence":"additional","affiliation":[{"name":"Stollery Children\u2019s Hospital University of Alberta , Edmonton, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Becker","sequence":"additional","affiliation":[{"name":"Driscoll Children\u2019s Hospital , Corpus Christi, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8081-0606","authenticated-orcid":false,"given":"Susana","family":"Armesto","sequence":"additional","affiliation":[{"name":"Hospital Universitario Marques de Valdecilla , Santander ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4225-6958","authenticated-orcid":false,"given":"Apostolos","family":"Kontzias","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-9948","authenticated-orcid":false,"given":"Rajneet K","family":"Oberoi","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Zhang","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Amouzadeh","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuoshun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0468-9568","authenticated-orcid":false,"given":"Lisa","family":"Arkin","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , Madison, WI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025111813165597000_ljaf305-B1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000450826","article-title":"Systematic review of health-related quality of life in adolescents with psoriasis","volume":"232","author":"Gonzalez","year":"2016","journal-title":"Dermatology"},{"key":"2025111813165597000_ljaf305-B2","first-page":"1057","article-title":"Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients","volume":"8","author":"Kelly","year":"2021","journal-title":"Children (Basel)"},{"key":"2025111813165597000_ljaf305-B3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in children and adolescents: diagnosis, management and comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Paediatr Drugs"},{"key":"2025111813165597000_ljaf305-B4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165597000_ljaf305-B5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2017.0499","article-title":"Pediatric psoriasis comorbidity screening guidelines","volume":"153","author":"Osier","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025111813165597000_ljaf305-B6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/pde.12416","article-title":"Effect of age at diagnosis on chronic quality of life and long-term outcomes of individuals with psoriasis","volume":"32","author":"Kim","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"2025111813165597000_ljaf305-B7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2011.11.948","article-title":"Risks of developing psychiatric disorders in pediatric patients with psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165597000_ljaf305-B8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s13555-022-00761-7","article-title":"Patient characteristics and treatment patterns in European pediatric patients with psoriasis: a real-world, cross-sectional study","volume":"12","author":"Sticherling","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025111813165597000_ljaf305-B9","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: update on treatments and challenges \u2013 a review","volume":"33","author":"Hebert","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025111813165597000_ljaf305-B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1546-0096-11-23","article-title":"Mothers\u2019 reports of the difficulties that their children experience in taking methotrexate for juvenile idiopathic arthritis and how these impact on quality of life","volume":"11","author":"Mulligan","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025111813165597000_ljaf305-B11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/09546634.2014.996515","article-title":"Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry","volume":"26","author":"van Geel","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"2025111813165597000_ljaf305-B12","article-title":"Real-world methotrexate use in a prospective cohort of paediatric patients with plaque psoriasis: effectiveness, adverse events and folic acid regimen","volume":"102","author":"Bruins","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025111813165597000_ljaf305-B13","volume-title":"Otezla [package insert]","year":"2024"},{"key":"2025111813165597000_ljaf305-B14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jaad.2023.11.068","article-title":"Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial","volume":"90","author":"Fiorillo","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165597000_ljaf305-B15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1])","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165597000_ljaf305-B16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf305\/63896100\/ljaf305.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1120\/63896100\/ljaf305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1120\/63896100\/ljaf305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:08Z","timestamp":1763489828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1120\/8219502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf305","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,30]]}}}